Emerging biotechs are accounting for an increasing proportion of approvals

The percentage of innovative drug approvals sponsored by emerging biotech companies (R&D expenditure < US $300m) between 2015 and 2024.

(Please use a modern browser to see the interactive version of this visualization)

Data accessed 4 April 2025. Innovator drugs refer to new molecular entities and non-new molecular entities and excludes generics and biosimilars.

Source: GlobalData, Pharmaceutical Intelligence Center, Drugs database.Get the dataCreated with Datawrapper